TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression. [electronic resource]
Producer: 20160822Description: 27252-66 p. digitalISSN:- 1949-2553
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Apoptosis
- CD8-Positive T-Lymphocytes -- cytology
- Carboxymethylcellulose Sodium -- analogs & derivatives
- Carcinoma, Hepatocellular -- pathology
- Cell Line, Tumor
- Cell Proliferation
- Cell Survival
- Disease Progression
- Extracellular Signal-Regulated MAP Kinases -- metabolism
- Humans
- Immune System
- Immunosuppressive Agents -- chemistry
- Liver Neoplasms -- pathology
- MAP Kinase Kinase Kinases -- metabolism
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Inbred NOD
- Mice, SCID
- Niacinamide -- administration & dosage
- Phenylurea Compounds -- administration & dosage
- Phosphorylation
- Poly I-C -- chemistry
- Polylysine -- analogs & derivatives
- Proto-Oncogene Proteins c-akt -- metabolism
- Signal Transduction
- Sorafenib
- Toll-Like Receptor 3 -- agonists
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.